Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 9/20 | 0.54 |
| ▸ | TDO2 | P48775 | 9/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.49 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29865102 | 1.00 | EIF4A3 (0.55) | EIF4A3IDO1TDO2MMP13KDM4E | |
| SCHEMBL3027767 | 0.88 | MMP13 (0.67) | IDO1TDO2MMP13KDM4EMAPT | |
| SCHEMBL28578488 | 0.87 | KDM4E (0.54) | EIF4A3KDM4EMAPTDAOHPGD | |
| SCHEMBL31383559 | 0.85 | MMP13 (0.60) | IDO1TDO2MMP13KDM4EMAPT | |
| SCHEMBL23045602 | 0.85 | MMP13 (0.60) | IDO1TDO2MMP13KDM4EMAPT | |
| SCHEMBL3636947 | 0.84 | MAPT (0.52) | EIF4A3IDO1TDO2KDM4EMAPT | |
| SCHEMBL3642811 | 0.81 | EIF4A3 (0.48) | EIF4A3IDO1TDO2KDM4EMAPT | |
| SCHEMBL28687276 | 0.80 | MMP13 (0.81) | MMP13KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL3035898 | 0.80 | LEF1 (0.49) | EIF4A3IDO1TDO2KDM4EMAPT | |
| SCHEMBL3633240 | 0.80 | EIF4A3 (0.54) | EIF4A3IDO1TDO2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2155675-B1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| CN-101790313-A | Compound (I) | SMITHKLINE BEECHAM CORP | 2010-07-28 | — | — | CN | disclosed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| EP-2155675-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | Provid Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2008156573-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | EIF4A3 3270/4885IDO1 1297/4885TDO2 1589/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | EIF4A3 1239/4885IDO1 908/4885TDO2 2054/4885 |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | EIF4A3 3102/4885IDO1 2951/4885TDO2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.